(VIR) Vir Biotechnology - Overview
Stock: Antibodies, Vaccines, T-Cell Engagers, Oncology, Infectious Diseases
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.8% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.25 |
| Alpha | -50.00 |
| Character TTM | |
|---|---|
| Beta | 1.511 |
| Beta Downside | 1.314 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.32% |
| CAGR/Max DD | -0.42 |
Description: VIR Vir Biotechnology December 24, 2025
Vir Biotechnology (NASDAQ:VIR) is a clinical-stage biopharma focused on discovering and developing therapeutics for serious infectious diseases, with a parallel effort targeting solid-tumor oncology indications.
The company’s pipeline includes an investigational therapy for hepatitis delta virus (HDV) and a suite of preclinical candidates against influenza A/B, SARS-CoV-2, RSV, human metapneumovirus, and HPV. Recent data from its HDV program showed a 70% reduction in viral load in a Phase 2 cohort, positioning it as a potential first-in-class treatment.
Vir leverages a network of strategic alliances: a grant from the Gates Foundation, a licensing deal with Brii Biosciences, a collaboration with Alnylam on RNA-targeted therapeutics, and a multi-product partnership with Sanofi that grants exclusive rights to its protease-cleavable masking platform for both oncology and infectious-disease T-cell engagers.
Financially, Vir reported $115 million in cash and marketable securities at the end of Q3 2024, giving it runway through 2026 without dilutive financing. The biotech sector’s growth is being driven by heightened investor appetite for pandemic-preparedness platforms and a 12% YoY increase in R&D spending across the industry, which supports Vir’s multi-pathogen strategy.
For a deeper dive into VIR’s valuation metrics and scenario analysis, consider exploring ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -499.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -13.59 > 1.0 |
| NWC/Revenue: 2790 % < 20% (prev 1183 %; Δ 1607 % < -1%) |
| CFO/TA -0.44 > 3% & CFO -453.5m > Net Income -499.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.9m) vs 12m ago 1.67% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.34% > 50% (prev 5.25%; Δ -3.91% > 0%) |
| Interest Coverage Ratio: -21.96 > 6 (EBITDA TTM -511.5m / Interest Expense TTM -23.8m) |
Altman Z'' -8.90
| A: 0.46 (Total Current Assets 545.7m - Total Current Liabilities 75.2m) / Total Assets 1.02b |
| B: -1.13 (Retained Earnings -1.15b / Total Assets 1.02b) |
| C: -0.42 (EBIT TTM -523.2m / Avg Total Assets 1.26b) |
| D: -5.18 (Book Value of Equity -1.16b / Total Liabilities 223.4m) |
| Altman-Z'' Score: -8.90 = D |
Beneish M -1.21
| DSRI: 3.52 (Receivables 4.00m/5.30m, Revenue 16.9m/78.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.59 (AQ_t 0.35 / AQ_t-1 0.22) |
| SGI: 0.21 (Revenue 16.9m / 78.6m) |
| TATA: -0.05 (NI -499.7m - CFO -453.5m) / TA 1.02b) |
| Beneish M-Score: -1.21 (Cap -4..+1) = D |
What is the price of VIR shares?
Over the past week, the price has changed by -3.36%, over one month by +20.64%, over three months by +40.43% and over the past year by -29.72%.
Is VIR a buy, sell or hold?
- StrongBuy: 2
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.1 | 138% |
| Analysts Target Price | 17.1 | 138% |
| ValueRay Target Price | 6 | -16% |
VIR Fundamental Data Overview February 03, 2026
P/S = 61.3933
P/B = 1.302
Revenue TTM = 16.9m USD
EBIT TTM = -523.2m USD
EBITDA TTM = -511.5m USD
Long Term Debt = 100.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.96m USD (from shortTermDebt, last quarter)
Debt = 100.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -69.9m USD (from netDebt column, last quarter)
Enterprise Value = 628.8m USD (1.04b + Debt 100.2m - CCE 506.5m)
Interest Coverage Ratio = -21.96 (Ebit TTM -523.2m / Interest Expense TTM -23.8m)
EV/FCF = -1.37x (Enterprise Value 628.8m / FCF TTM -460.4m)
FCF Yield = -73.23% (FCF TTM -460.4m / Enterprise Value 628.8m)
FCF Margin = -2731 % (FCF TTM -460.4m / Revenue TTM 16.9m)
Net Margin = -2964 % (Net Income TTM -499.7m / Revenue TTM 16.9m)
Gross Margin = unknown ((Revenue TTM 16.9m - Cost of Revenue TTM 455.4m) / Revenue TTM)
Tobins Q-Ratio = 0.62 (Enterprise Value 628.8m / Total Assets 1.02b)
Interest Expense / Debt = 0.24% (Interest Expense 239.0k / Debt 100.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -413.3m (EBIT -523.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.25 (Total Current Assets 545.7m / Total Current Liabilities 75.2m)
Debt / Equity = 0.13 (Debt 100.2m / totalStockholderEquity, last quarter 796.1m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -69.9m / EBITDA -511.5m)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -69.9m / FCF TTM -460.4m)
Total Stockholder Equity = 984.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.69% (Net Income -499.7m / Total Assets 1.02b)
RoE = -50.75% (Net Income TTM -499.7m / Total Stockholder Equity 984.4m)
RoCE = -48.24% (EBIT -523.2m / Capital Employed (Equity 984.4m + L.T.Debt 100.2m))
RoIC = -41.99% (negative operating profit) (NOPAT -413.3m / Invested Capital 984.4m)
WACC = 10.48% (E(1.04b)/V(1.14b) * Re(11.48%) + D(100.2m)/V(1.14b) * Rd(0.24%) * (1-Tc(0.21)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.59%
Fair Price DCF = unknown (Cash Flow -460.4m)
EPS Correlation: -44.49 | EPS CAGR: -27.42% | SUE: 1.65 | # QB: 1
Revenue Correlation: -42.38 | Revenue CAGR: -88.55% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.037 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.92 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+12.0% | Growth Revenue=-58.6%